Celgene and Novartis Pharmaceuticals filed suit against Actavis over six patents related to drug formulations having diminished abuse potential. 11/4, District of New Jersey, 2:2011cv06519.
Access to the full article is currently available to RPX members only. Please contact us if you need further information.
